Recurrent malignant gliomas carry a poor prognosis, and targeted therapy is an area of active investigation. A noninvasive biomarker that accurately assesses the treatment response with prognostic value is critically needed. Schwarzenberg and colleagues examine the amino-acid-analogue L-3,4-dihydroxy-6-18F-fluorophenyl-alanine (18F-FDOPA) PET imaging in patients with recurrent high-grade malignant gliomas on antiangiogenic treatment with bevacizumab. This biomarker predicted treatment response successfully as early as 1 to 2 weeks after starting therapy and provided prognostic information. The results of the study can guide the selection of treatment for these patients by identifying responders from nonresponders at an early time after starting therapy.

The identification of mutated tumor antigens, which have been found in many cases to represent the predominant targets of tumor-reactive T cells, remains a challenging and time-consuming process. In an attempt to streamline this process, Lu and colleagues developed a novel genetic strategy that involved the screening...

You do not currently have access to this content.